Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946798 · ClinicalTrials.gov registry record · Early Phase 1
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
A Early Phase 1 study of Gestational Diabetes and Oxidative Stress, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05946798 is a Early Phase 1 study of Gestational Diabetes and Oxidative Stress that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 40 participants, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05946798, a Early Phase 1 study of Gestational Diabetes and Oxidative Stress, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.
Conditions Studied
Interventions
- DRUG Acetylcholine
- DRUG Insulin aspart
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2028-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05946798
The ClinicalTrials.gov registry entry for NCT05946798 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gestational Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Acetylcholine is the first listed.
NCT05946798 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05946798 about?
NCT05946798 is a clinical study titled "Role of NADPH Oxidase in Microvascular Dysfunction Following GDM". The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.
What is the current status of trial NCT05946798?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-30. Estimated completion is 2028-06-01.
What conditions does trial NCT05946798 study?
This clinical trial studies the following conditions: Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function.
What interventions are being tested in trial NCT05946798?
The interventions under investigation include: Acetylcholine (DRUG), Insulin aspart (DRUG).
Who is sponsoring clinical trial NCT05946798?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05946798 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
RECRUITING · Early Phase 1
-
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
RECRUITING · Early Phase 1
-
Soy Supplementation and Gestational Diabetes
COMPLETED · Early Phase 1
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.